Patent Issued for Agents for reversing toxic proteinopathies (USPTO 12023308).

A patent has been issued to Broad Institute Inc. for agents that can reverse toxic proteinopathies, which are diseases caused by genetic mutations resulting in the accumulation of misfolded proteins in cells. The patent describes the identification of a compound called BRD-4780, which has been found to effectively treat MUC1-associated kidney disease and other toxic proteinopathies. The compound works by reducing the accumulation of mutant proteins in the early secretory pathway of cells. This patent provides potential methods for treating uromodulin kidney disease and includes various claims related to the administration of the compound. [Extracted from the article]